Do Alpha Agonists Increase Venous Return?
Gelman, Simon M.D., Ph.D.*; Mushlin, Phillip S. M.D., Ph.D.
We thank Dr. Butterworth for his attention to our work.1
He is correct: There is still confusion about the effects of α agonists on venous return. In fact, Dr. Butterworth’s letter is confusing. First, he refers to Yamazaki et al.
arguing that hypotension induced by spinal anesthesia and ganglionic blockade in dogs is “analogous to hypovolemia.” How could this be true? Clearly, the dogs are normovolemic; the arterial hypotension results mainly from vasodilation and redistribution of blood into the splanchnic vasculature. Hypovolemia, in contrast, empties the splanchnic reservoir. Yamazaki et al.2
show that α-adrenergic agonists increase venous return, which is exactly what we say in the sentence that Dr. Butterworth quotes from our article. He then refers to Supple et al.
whose study supports our viewpoint that α-adrenergic agonists can increase venous return. Indeed, the first two references offered by him to refute our position strongly support it.
Dr. Butterworth next cites Imai et al.
noting that α-adrenergic agonists decrease venous return, as is also stated in our article mentioning the same publication. The study by Imai et al.
shows that methoxamine decreases venous return, but only at high doses. Dr. Butterworth does not mention that in dogs pretreated with a vasodilator, methoxamine increases venous return, ostensibly by reversing vasodilator-induced pooling of blood in the splanchnic vasculature, which again supports our position.
Then, Dr. Butterworth refers to his own study—and misquotes it.5
In his letter, he writes, “we found that phenylephrine … decreased venous return.”5
His article, however, states that phenylephrine “had no clear effect on reservoir volume.”5
Besides, Dr. Butterworth et al.
studied splenectomized dogs, which are likely to be hypovolemic because of the large blood volume removed with the spleen. They excluded two dogs because of “unexplained metabolic acidosis.” If splenectomy caused the hypovolemia, the “unexplained” becomes explicable, i.e.
, metabolic acidosis from hypoperfusion. After reviewing Dr. Butterworth’s data, we understand a source of the confusion. Phenylephrine decreased mean reservoir volume in the highest-dose group but not in the lower-dose groups.5
The difference was not statistically significant, in part because of the more variable responses among dogs given high-dose phenylephrine. Ironically, Dr. Butterworth’s data support our view that both the dose of α agonist and the degree of hypovolemia determine the net effect of α agonists on venous return.
Dr. Butterworth refers to three more studies6–8
to prove that low doses of α-adrenergic agonists decrease venous return. However, in each study, the α agonist increased blood pressure and decreased heart rate, reflecting a baroreflex response. Baroreceptor activation itself dilates splanchnic veins, shifts blood into the splanchnic vasculature, and decreases venous return.9,10
The authors of one study7
admit that their observation “does not necessarily conflict with the findings that α-receptor stimulation can also result in increased venous return” (page 527). The final reference that Dr. Butterworth cites11
shows that α agonists increase venous reservoir volume, reinforcing our position that α agonists can increase venous return.
References 27 and 33–35 in our original article1
provide support for our opinion. Many other studies support our position that α agonists can increase venous return12–17
; some focus on the matter in dispute. Stokland et al.
using a model in which preload was controllable, showed that two thirds of the phenylephrine-induced increase in blood pressure resulted from increased preload, whereas only one third was from increased peripheral vascular resistance. Richer et al.13
showed that low doses of α agonists increase venous return, whereas high doses decrease it, which directly conflicts with Dr. Butterworth’s viewpoint and affirms ours.
The basis for the confusion about α agonists lies in their abilities to constrict splanchnic preportal veins and hepatic resistance veins simultaneously. Constricting the former shifts splanchnic blood to the central circulation; constricting the latter impedes the shift. With high doses of α agonists, the effects on hepatic venous resistance can trap blood within the liver.4
Finally, we are happy to note that Dr. Butterworth’s letter closes by stressing a key message in our article, namely that “intense vasoconstriction can be detrimental … and should not be viewed as a substitute for the immediate replacement of blood volume.”1
Simon Gelman, M.D., Ph.D., *
Phillip S. Mushlin, M.D., Ph.D.
* Brigham and Women’s Hospital, Boston, Massachusetts. email@example.com
1. Gelman S, Mushlin PS: Catecholamine-induced changes in the splanchnic circulation affecting systemic hemodynamics. Anesthesiology 2004; 100:434–9
2. Yamazaki R, Tsuchida K, Aihara H: Effects of alpha-adrenoceptor agonists on cardiac output and blood pressure in spinally anesthetized ganglion-blocked dogs. Arch Int Pharmacodyn Ther 1988; 295:80–93
3. Supple EW, Graham RM, Powell WJ Jr: Direct effects of alpha 2-adrenergic receptor stimulation on intravascular systemic capacity in the dog. Hypertension 1988; 11:352–9
4. Imai Y, Satoh K, Taira N: Role of the peripheral vasculature in changes in venous return caused by isoproterenol, norepinephrine, and methoxamine in anesthetized dogs. Circ Res 1978; 43:553–61
5. Butterworth JF IV, Piccione W Jr, Berrizbeitia LD, Dance G, Shemin RJ, Cohn LH: Augmentation of venous return by adrenergic agonists during spinal anesthesia. Anesth Analg 1986; 65:612–6
6. Bell L, Zaret BL, Rutlen DL: Influence of alpha-adrenergic receptor stimulation on splanchnic intravascular volume in conscious humans. Acta Physiol Scand 1991; 143:65–9
7. Leenen FH, Chan YK, Smith DL, Reeves RA: Epinephrine and left ventricular function in humans: Effects of beta-1 vs nonselective beta-blockade. Clin Pharmacol Ther 1988; 43:519–28
8. Brooker RF, Butterworth JF IV, Kitzman DW, Berman JM, Kashtan HI, McKinley AC: Treatment of hypotension after hyperbaric tetracaine spinal anesthesia: A randomized, double-blind, cross-over comparison of phenylephrine and epinephrine. Anesthesiology 1997; 86:797–805
9. Shoukas AA, Sagawa K: Control of total systemic vascular capacity by the carotid sinus baroreceptor reflex. Circ Res 1973; 33:22–33
10. Shoukas AA, Brunner MC: Epinephrine and the carotid sinus baroreceptor reflex. Influence on capacitive and resistive properties of the total systemic vascular bed of the dog. Circ Res 1980; 47:249–57
11. Muller-Ruchholtz ER, Losch HM, Grund E, Lochner W: Effect of alpha adrenergic receptor stimulation on integrated systemic venous bed. Pflugers Arch Eur J Physiol 1977; 370:241–6
12. Stokland O, Thorvaldson J, Ilebekk A, Kiil F: Factors contributing to blood pressure elevation during norepinephrine and phenylephrine infusions in dogs. Acta Physiol Scand 1983; 117:481–9
13. Richer C, Lefevre-Borg F, Lechaire J, Gomeni C, Gomeni R, Giudicelli JF, Cavero I: Systemic and regional hemodynamic characterization of alpha-1 and alpha-2 adrenoceptor agonists in pithed rats. J Pharmacol Exp Ther 1987; 240:944–53
14. Zandberg P, Timmermans PB, van Zwieten PA: Hemodynamic profiles of methoxamine and B-HT 933 in spinalized ganglion-blocked dogs. J Cardiovasc Pharmacol 1984; 6:256–62
15. Appleton C, Olajos M, Morkin E, Goldman S: Alpha-1 adrenergic control of the venous circulation in intact dogs. J Pharmacol Exp Ther 1985; 233:729–34
16. Hiley CR, Thomas GR: Effects of alpha-adrenoceptor agonists on cardiac output and its regional distribution in the pithed rat. Br J Pharmacol 1987; 90:61–70
17. MacLean MR, Hiley CR: Effects of enalapril on changes in cardiac output and organ vascular resistances induced by alpha 1- and alpha 2-adrenoceptor agonists in pithed normotensive rats. Br J Pharmacol 1988; 94:449–62
© 2004 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.